Labopharm Inc: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-24

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Labopharm, formerly known as Centre de Recherche Appliquee Pharmaceutique (CRAP), is a specialty pharmaceutical company optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies: Contramid and PNDS. . It is currently focusing on developing and commercializing its lead product candidate, Trazodone for the potential treatment of depression.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    Labopharm's primary focus is developing small molecule drugs for two therapeutic indications, pain and depression. The company currently has one marketed product, Tramadol, indicated for moderate to severe pain, in Europe and Canada through its marketing partners. Trazodone, indicated for depression is currently in Phase III clinical development.

    The company's total revenues increased at a CAGR of 102.9% during 2002-2006, from $0.8 million to $14 million. This represents an absolute total growth of +$13.1 million for total revenues during the same period. License, collaboration and other revenues are a major contributor to revenue growth by contributing +$7.1 million.

    The company's biggest contributor to sales growth out to 2010 again will be revenues from license, collaboration and other. Revenues from license, collaboration and other are expected to increase from $8 million in 2006 to $75 million in 2010, recording an absolute growth of +$67 million.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: labopharm betahistine sales tripp swot playle tony sylvie trazodone consultant

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.